In 1999, NIDA began allowing the sale of research-grade marijuana to private researchers, opening the door for clinical studies on pain, AIDS wasting, and nausea.
What the researchers found
This review surveyed the history of marijuana as a medical substance and the state of cannabis research at the close of the 20th century. It highlighted the longstanding tension between marijuana's widespread historical use and the legal barriers that had constrained modern scientific investigation.
A notable development was NIDA's 1999 decision to begin selling research-grade marijuana to private researchers, ending the agency's monopoly on who could study the substance. This policy change was expected to accelerate clinical research.
The article identified pain management, AIDS-related wasting syndrome, and chemotherapy-induced nausea as the most promising therapeutic targets for cannabis-based treatments.
Why it matters
By 1999, medical marijuana laws were spreading across states, but rigorous clinical research remained scarce due to federal restrictions on cannabis supply. NIDA's policy shift represented a meaningful reduction in one of the biggest barriers to studying marijuana's medical potential.
The numbers in context
NIDA began selling research marijuana to private researchers in 1999. Pain, AIDS wasting, and chemotherapy-induced nausea were identified as primary therapeutic targets.
How the study worked
This was a narrative review published in a perspectives journal. The author surveyed historical uses of marijuana, summarized the contemporary regulatory landscape, and identified areas of therapeutic promise based on existing preliminary evidence and clinical interest.
What this study cannot tell us
This was an opinion and perspectives piece rather than a systematic review. It did not evaluate the strength of existing clinical evidence for any therapeutic indication. The research landscape it described has changed substantially since 1999.
How to read the evidence
A narrative perspectives piece summarizing the research landscape rather than presenting original clinical data.
The bigger picture
This article captured a pivotal moment when regulatory barriers to cannabis research began to soften. The challenges it described, including limited access to research-grade material and the gap between patient demand and clinical evidence, would persist for decades and continue to shape the medical cannabis debate.
Common questions
Why was it hard to study marijuana medically before 1999?
What medical uses showed the most promise in 1999?
Read the original research
Marijuana mania.
STEP perspective, 99(2), 2-3, 6
Citation
Syracopoulos, T. (1999). Marijuana mania.. STEP perspective, 99(2), 2-3, 6.